Therapeutics– tag –

1. Where Does AI in Drug Discovery Stand in 2025? Between 2024 and 2025, AI in drug discovery has quietly moved from the “proof-of-concept” phase into a stage where AI-designed molecules are showing signals in human trials. At the same t...

1. Recap: A Cross-Modality “AI in Drug Discovery” Map In Parts 1–6, we walked through: Small molecules × AI Antibodies, bispecifics, and ADCs × AI Nucleic acid and RNA therapeutics × AI Cell and gene therapies × AI Each time, we looked a...

1. Why “Cell & Gene Therapy × AI” Is Both Difficult and Important In Part 6, we focus on cell therapies (e.g., CAR-T, TCR-T) and gene therapies (e.g., AAV or lentiviral vectors). Compared with small molecules, antibodies, or RNA ther...

Introduction: Aging Is Becoming an Industry In Extra Edition Part 1, we introduced the concept of “anti-aging drugs” by looking at major mechanisms such as mTOR, metformin, senolytics, NAD⁺, and cellular reprogramming. We focused on how ...

In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions) is hard to interpret and why genome AI should be framed as hypothesis generation and prioritization, not as an “answer machine.” This Expert Edition g...

Introduction: Why Are “Anti-Aging Drugs” a Hot Topic Now? When you hear “anti-aging drugs” or “rejuvenation pills,” you might imagine dubious supplements or flashy beauty ads. However, what many academic groups, pharmaceutical companies,...

When people hear “genome analysis,” they often imagine a simple story: read DNA, find a mutation, and explain a disease. In reality, the deeper we read, the more often we hit a frustrating wall: we can detect many variants, but we can’t ...

1. Why “Nucleic Acid & RNA Therapeutics × AI” Matters mRNA vaccines, siRNA, antisense oligonucleotides (ASOs), saRNA, and CRISPR guide RNAs have rapidly moved from concept to clinical reality. In these modalities, the design space is...

Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging environment to study. The blood–brain barrier (BBB) and the inherently low-biomass nature of brain tissue make it difficult to me...

1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-molecule projects. In Part 4, we turn to antibodies and biologics (including antibodies, bispecifics, antibody–drug conjugates, and...

FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V...

1. Why Small Molecules Became the Primary Testbed for AI When you scan AI-in-drug-discovery papers and case studies, the first thing you notice is how many of them focus on small molecules. This is not just because small-molecule R&D...

The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infectious disease, and it also happens in cancer.In most cases, the problem is not a lack of knowledge. The problem is structural: w...

1. Data and Models: The Core of AI in Drug Discovery In Part 1, we mapped where AI can plug into the drug discovery and development value chain and what it can – and cannot – do. In Part 2, we zoom in on the foundations: data and models....

1. Why AI in Drug Discovery Is in the Spotlight Now “AI in drug discovery” has become a buzzword in recent years, but it is not a magic technology that appeared overnight. Traditional in silico approaches – QSAR, docking, and statistical...

At JPM2026, CEO remarks drew outsized attention. The reason is straightforward: professional investors already track patent cliffs, revenue concentration, and forward sales trajectories. What they want from JPM is not “nice words,” but a...

One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true mega-M&A headlines were scarce. That is not an anomaly. It reflects a structural optimization driven by today’s capital costs, integ...

At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the most decisive conversations were not about incremental clinical deltas or “which molecule is best.” The battleground has shift...

This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. We align breast, ovarian, and endometrial cancer considerations ...

Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif...